Biomarker Discovery

Use AI to accelerate biomarker discovery for early diagnosis and personalized treatment

Business impact

• Diagnostic accuracy — Improved biomarker detection leads to more precise and earlier disease diagnosis
• Time to diagnosis — AI accelerates biomarker discovery, shortening the time needed for diagnosis
• Research productivity — Automated data analysis increases throughput and efficiency in biomarker research
• Treatment efficacy — Better biomarkers enable personalized therapies, improving patient response rates
• Cost reduction — Faster discovery and experimental design reduce overall drug development expenses

Data requirements

• Genomic sequencing data (Structured) — Used to identify genetic variants linked to disease biomarkers
• Proteomic profiles (Numeric) — Provide dynamic protein expression data critical for biomarker discovery
• Transcriptomic data (Numeric) — Capture RNA expression patterns to complement biomarker identification
• Imaging data (e.g., multiplex fluorescence) (Image) — Reveal spatial protein expression and tumor microenvironment context
• Clinical records (Text) — Correlate biomarker presence with patient outcomes and disease progression

AI methods and techniques

• Predictive AI — Models predict biomarker relevance and disease risk from complex datasets
• Generative AI — Generates hypotheses and molecular data to expand biomarker candidate libraries
• Agentic AI — Automates experimental design and data curation workflows for biomarker research

AI models and model families

GPT-4o, Claude, Llama, GPT-Rosalind

Industries

Real-world evidence

18 documented case studies on record.

Companies using this: Abbott Laboratories, Agilent Technologies, Anthropic, Clues, Frontiers, Generare Bioscience, Hologic, Illumina, Infleqtion, Johnson & Johnson, Kivo, Lunit, M, Multivision Dx, Roche Holding AG and 3 more.